Searched for
MSD PHARMA
Stocks in news: Rajesh Exports, Lenskart, Suzlon Energy, Aurobindo Pharma, Tata MotorsIndian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced i...- Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facilityAurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- MSD India ropes in Madhuri Dixit for cervical cancer awareness driveUS pharma major MSD has partnered with Bollywood actor Madhuri Dixit for a nationwide cervical cancer awareness program in India. The initi...
- Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
- Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & ...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Panel to meet today to take up applications seeking nod for MolnupiravirThe firms whose applications that will be taken up are Dr Reddy's Laboratories which has filed for approval in a consortium with five other...
- Sun Pharma says gearing up to launch COVID drug molnupiravirThe company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...
- MSD enters pact with UN-backed MPP to license COVID drug molnupiravir in 105 countries including IndiaUnder the terms of the agreement, MPP will be permitted to further license non-exclusive sub-licences to manufacturers and diversify the ma...
- MSD to sign licensing pacts with 5 Indian drug firms for oral drug candidate for COVID-19MSD has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufactur...
- Glenmark's anti-diabetes drugs shake up Indian anti-diabetes marketThe company has raked in Rs 16 crore in just 8 months since drug was launched.
- Lupin to market MSD's pneumonia prevention vaccine in IndiaAs part of the agreement promote and distribute MSD's 23-valent Pneumococcal Polysaccharide Vaccine under a different brand name in the cou...
- Drug makers accuse V Mohan of possible conflict of interest in getting diabetes drug Pioglitazone bannedIn January this year, Mohan had written a letter to the Prime Minister’s Office, detailing the risks of bladder cancer caused by the prolon...
- Sun Pharma gets FDA nod for generic version of JanuviaThis comes as a surprise as Sun has partnered the US based MSD in the domestic market to sue Glenmark for the patent infringement on the sa...
- No interim relief to Merck against Glenmark’s diabetes genericsDelhi High Court has refused to bar Glenmark from selling the generic versions of anti-diabetic drugs manufactured by Merck Sharp & Dohme.
- HCL signs $500 mn IT deal with US pharma giant MSDHCL will provide services like IT solutions, remote infrastructure management, engineering & business & knowledge process services. Perform...
Load More
